#VYKAT_XR
LightNews LightNews
newsen.bsky.social
Neurocrine Biosciences Showcases PWS Research and VYKAT XR at 2026 Conference#USA#Philadelphia#Neurocrine#VYKAT_XR#Prader-Willi_Syndrome
Neurocrine Biosciences Showcases PWS Research and VYKAT XR at 2026 Conference
Neurocrine Biosciences presents crucial research at the Foundation for Prader-Willi Research Symposium focusing on VYKAT XR for Prader-Willi Syndrome.
third-news.com
September 30, 2026 at 12:44 PM
newsen.bsky.social
LogiCare3PL Aids Launch of Soleno Therapeutics' Groundbreaking VYKAT XR Therapy#United_States#Olive_Branch#VYKAT_XR#LogiCare3PL#Soleno_Therapeutics
LogiCare3PL Aids Launch of Soleno Therapeutics' Groundbreaking VYKAT XR Therapy
LogiCare3PL proudly supports the launch of Soleno Therapeutics' VYKAT™ XR, the first FDA-approved treatment for hyperphagia linked to Prader-Willi syndrome.
third-news.com
April 28, 2025 at 1:19 PM
newsen.bsky.social
Soleno Therapeutics Unveils Long-Term Benefits of VYKAT XR for Prader-Willi Syndrome at ENDO 2026#USA#San_Diego#Neurocrine_Biosciences#VYKAT_XR#Prader-Willi_Syndrome
Soleno Therapeutics Unveils Long-Term Benefits of VYKAT XR for Prader-Willi Syndrome at ENDO 2026
Discover the latest findings on VYKAT XR's enduring impacts on Prader-Willi Syndrome from ENDO 2026, promising hope for enduring treatment success.
third-news.com
June 15, 2026 at 8:14 PM
newsen.bsky.social
Hagens Berman Alerts Investors About Soleno Therapeutics Class Action Over Drug Launch Issues#United_States#San_Francisco#Hagens_Berman#VYKAT_XR#Soleno_Therapeutics
Hagens Berman Alerts Investors About Soleno Therapeutics Class Action Over Drug Launch Issues
Hagens Berman notifies investors of a class action lawsuit against Soleno Therapeutics over alleged misleading claims regarding its drug, VYKAT™ XR.
third-news.com
May 11, 2026 at 5:45 PM
newsen.bsky.social
Serious Allegations Against Soleno Therapeutics in Securities Fraud Lawsuit Raise Investor Concerns#USA#New_York#VYKAT_XR#Soleno_Therapeutics#DCCR
Serious Allegations Against Soleno Therapeutics in Securities Fraud Lawsuit Raise Investor Concerns
Soleno Therapeutics faces serious class action allegations regarding clinical trial conduct. Investors with losses may lead the lawsuit amid concerns over drug safety and efficacy.
third-news.com
April 29, 2026 at 1:57 PM
newsen.bsky.social
Hagens Berman Warns Investors of Soleno Therapeutics Class Action Over Drug Launch Issues#United_States#San_Francisco#Hagens_Berman#VYKAT_XR#Soleno_Therapeutics
Hagens Berman Warns Investors of Soleno Therapeutics Class Action Over Drug Launch Issues
Hagens Berman alerts investors of an impending class action against Soleno Therapeutics regarding launch disruptions of its PWS treatment, urging them to act before the deadline.
third-news.com
April 27, 2026 at 10:39 PM
newsen.bsky.social
Soleno Therapeutics Faces Class Action Over Alleged Safety Issues in VYKAT XR Launch#USA#New_York#Securities_Fraud#VYKAT_XR#Soleno_Therapeutics
Soleno Therapeutics Faces Class Action Over Alleged Safety Issues in VYKAT XR Launch
Major concerns arise regarding Soleno Therapeutics' VYKAT XR safety post-launch. Investors might seek class action leading roles amid allegations of fraud.
third-news.com
April 22, 2026 at 2:29 PM
newsen.bsky.social
Opportunities for Soleno Therapeutics Investors Amid Class Action Notice#USA#San_Francisco#Hagens_Berman#VYKAT_XR#Soleno_Therapeutics
Opportunities for Soleno Therapeutics Investors Amid Class Action Notice
Investors in Soleno Therapeutics should note the upcoming class action aimed at those suffering significant losses during the Class Period.
third-news.com
April 13, 2026 at 11:31 PM
newsen.bsky.social
Neurocrine's Acquisition of Soleno: A New Era in Rare Disease Treatment#United_States#San_Diego#Neurocrine_Biosciences#VYKAT_XR#Soleno_Therapeutics
Neurocrine's Acquisition of Soleno: A New Era in Rare Disease Treatment
Neurocrine Biosciences is set to acquire Soleno Therapeutics for $2.9 billion, enhancing its portfolio with the groundbreaking treatment for Prader-Willi syndrome.
third-news.com
April 6, 2026 at 11:11 AM
newsen.bsky.social
Investigation Launched After Soleno's DCCR Issues Lead to Share Value Drop#United_States#San_Francisco#VYKAT_XR#Soleno_Therapeutics#DCCR
Investigation Launched After Soleno's DCCR Issues Lead to Share Value Drop
A recent lawsuit against Soleno Therapeutics highlights significant investor concerns following disappointing news about its DCCR product, impacting share prices.
third-news.com
April 1, 2026 at 7:56 PM
newsen.bsky.social
Investors Raise Alarm Over Soleno Therapeutics Amid Class Action Lawsuit Alleging Fraudulent Clinical Trials#USA#New_York#Joseph_Levi#VYKAT_XR#Soleno_Therapeutics
Investors Raise Alarm Over Soleno Therapeutics Amid Class Action Lawsuit Alleging Fraudulent Clinical Trials
Investors in Soleno Therapeutics face legal action over claims of falsified clinical trial data, raising concerns about the safety of its drug DCCR. Seek compensation now.
third-news.com
April 1, 2026 at 1:58 PM
newsen.bsky.social
Soleno Therapeutics Faces Class Action Over Troubling Drug Launch and Investor Lawsuit#United_States#San_Francisco#VYKAT_XR#Soleno_Therapeutics#Hyperphagia
Soleno Therapeutics Faces Class Action Over Troubling Drug Launch and Investor Lawsuit
Soleno Therapeutics' recent drug launch has led to a significant investor lawsuit amid serious safety concerns regarding its product intended for rare genetic disorder treatment.
third-news.com
March 26, 2026 at 9:52 PM
newsen.bsky.social
Investors Seek Justice: Soleno Therapeutics Faces Class Action Over Alleged Fraud#United_States#New_York#VYKAT_XR#Soleno_Therapeutics#DCCR
Investors Seek Justice: Soleno Therapeutics Faces Class Action Over Alleged Fraud
Soleno Therapeutics, Inc. faces a securities fraud lawsuit as investors claim misrepresentations about DCCR's safety. Affected shareholders may seek to lead the class action.
third-news.com
March 26, 2026 at 2:16 PM
newsen.bsky.social
Soleno Therapeutics Confronts Legal Action as DCCR Launch Faces Troubles#United_States#San_Francisco#VYKAT_XR#Soleno_Therapeutics#DCCR
Soleno Therapeutics Confronts Legal Action as DCCR Launch Faces Troubles
Soleno Therapeutics, facing a class action lawsuit, confronts challenges regarding the launch of its hyperphagia drug, DCCR, and its market impact.
third-news.com
March 24, 2026 at 5:25 PM
newsen.bsky.social
Soleno Therapeutics Faces Securities Class Action Over DCCR Drug Launch Issues#USA#Class_Action#San_Francisco#VYKAT_XR#Soleno_Therapeutics
Soleno Therapeutics Faces Securities Class Action Over DCCR Drug Launch Issues
Soleno Therapeutics, Inc. is embroiled in a securities class action lawsuit following poor performance reports of its drug DCCR. Investors are encouraged to respond.
third-news.com
March 20, 2026 at 8:23 PM
newsen.bsky.social
Investors Allege Fraud in Soleno Therapeutics Clinical Trials, Seek Class Action Status#USA#New_York#FDA_Approval#VYKAT_XR#Soleno_Therapeutics
Investors Allege Fraud in Soleno Therapeutics Clinical Trials, Seek Class Action Status
A pending class action lawsuit against Soleno Therapeutics, Inc. claims that the company's clinical trials for a key drug were flawed. Investors may pursue compensation for their losses.
third-news.com
March 19, 2026 at 1:51 PM
newsen.bsky.social
Soleno Therapeutics Faces Legal Challenge Amid Launch Issues of Hyperphagia Drug VYKAT™ XR#USA#Class_Action#San_Francisco#VYKAT_XR#Soleno_Therapeutics
Soleno Therapeutics Faces Legal Challenge Amid Launch Issues of Hyperphagia Drug VYKAT™ XR
Soleno Therapeutics is under scrutiny with a class action lawsuit due to concerns regarding its newly launched hyperphagia drug, VYKAT™ XR. Investors react.
third-news.com
March 18, 2026 at 3:50 PM
newsen.bsky.social
Soleno Therapeutics Faces Investor Class Action Over Drug Launch Issues#United_States#Class_Action#San_Francisco#VYKAT_XR#Soleno_Therapeutics
Soleno Therapeutics Faces Investor Class Action Over Drug Launch Issues
Soleno Therapeutics is facing a securities class action lawsuit related to its hyperphagia drug launch disruptions, as investors report significant losses.
third-news.com
March 16, 2026 at 7:16 PM
newsen.bsky.social
Soleno Therapeutics Faces Class Action Over Hyperphagia Drug and Its Troubled Launch#United_States#San_Francisco#VYKAT_XR#Soleno_Therapeutics#Hyperphagia
Soleno Therapeutics Faces Class Action Over Hyperphagia Drug and Its Troubled Launch
Soleno Therapeutics is facing a class action lawsuit concerning their hyperphagia drug launch. Investors are encouraged to share their losses as the company navigates significant challenges.
third-news.com
March 12, 2026 at 9:17 PM
newsen.bsky.social
Legal Challenges Mount for Soleno Therapeutics Amid Drug Launch Issues and Investor Lawsuit#United_States#Class_Action#San_Francisco#VYKAT_XR#Soleno_Therapeutics
Legal Challenges Mount for Soleno Therapeutics Amid Drug Launch Issues and Investor Lawsuit
Soleno Therapeutics faces a securities class action lawsuit following disappointing drug launch results. Investors seek redress amid safety concerns.
third-news.com
March 10, 2026 at 8:06 PM
newsen.bsky.social
Pomerantz Law Firm Investigates Possible Securities Fraud at Soleno Therapeutics, Inc.#USA#New_York#Pomerantz_Law_Firm#VYKAT_XR#Soleno_Therapeutics
Pomerantz Law Firm Investigates Possible Securities Fraud at Soleno Therapeutics, Inc.
The Pomerantz Law Firm is probing claims regarding Soleno Therapeutics, Inc. amid reports of significant stock price drops due to potential safety concerns.
third-news.com
January 8, 2026 at 3:55 PM
newsen.bsky.social
Pomerantz Law Firm Probes Potential Securities Fraud at Soleno Therapeutics#United_States#New_York#Pomerantz_Law_Firm#VYKAT_XR#Soleno_Therapeutics
Pomerantz Law Firm Probes Potential Securities Fraud at Soleno Therapeutics
The Pomerantz Law Firm is currently investigating claims on behalf of investors in Soleno Therapeutics, Inc. regarding potential securities fraud and adverse business practices.
third-news.com
January 1, 2026 at 3:17 PM
newsen.bsky.social
Investor Concerns Rise as Pomerantz Law Firm Investigates Soleno Therapeutics for Fraud Allegations#USA#New_York#Pomerantz_Law#VYKAT_XR#Soleno_Therapeutics
Investor Concerns Rise as Pomerantz Law Firm Investigates Soleno Therapeutics for Fraud Allegations
Pomerantz Law Firm is probing investor claims against Soleno Therapeutics, following significant stock drops after safety concerns over its product, Vykat XR.
third-news.com
December 11, 2025 at 3:54 PM
newsen.bsky.social
Robbins Geller Starts Investigation into Soleno Therapeutics Over Securities Violations#USA#Robbins_Geller#San_Diego#VYKAT_XR#Soleno_Therapeutics
Robbins Geller Starts Investigation into Soleno Therapeutics Over Securities Violations
Robbins Geller Rudman & Dowd LLP has initiated an investigation into Soleno Therapeutics for potential violations of federal securities laws, urging investors to come forward.
third-news.com
November 8, 2025 at 12:33 AM
newsen.bsky.social
Soleno Therapeutics Faces Investor Backlash After VYKATÔ XR Disappointments and Stock Price Plunge#USA#San_Francisco#investor_scrutiny#VYKAT_XR#Soleno_Therapeutics
Soleno Therapeutics Faces Investor Backlash After VYKATÔ XR Disappointments and Stock Price Plunge
Soleno Therapeutics' recent challenges with VYKAT™ XR and a sharp stock decline have prompted a detailed investigation into its communications and practices.
third-news.com
November 7, 2025 at 3:14 PM